Quantifying insulin receptor isoform expression in FFPE breast tumors

Growth Hormone and IGF Research

Volumn 22, Issue 3-4, 2012, Pages 108-115

  Harrington, Sean C ^a   Weroha, S John ^a   Reynolds, Carol ^a   Suman, Vera J ^a   Lingle, Wilma L ^a   Haluska, Paul ^a  

^a MAYO CLINIC   (United States)

Author keywords

Breast cancer; Monoclonal antibodies therapeutic use; Protein kinase inhibitors; QPCR; Real time; Receptor IGF Type 1; Receptor insulin

Indexed keywords

INSULIN RECEPTOR; INSULIN RECEPTOR A; INSULIN RECEPTOR B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

AMPLICON; ARTICLE; BREAST CANCER; BREAST TUMOR; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE HORMONE REFRACTORY BREAST CANCER; FEASIBILITY STUDY; FORMALIN FIXEDPARAFFIN EMBEDDED TISSUE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SENSITIVITY ANALYSIS; TISSUE PREPARATION; VALIDATION PROCESS;

ANTIGENS, CD; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; RECEPTOR, INSULIN; RECEPTORS, ESTROGEN;

EID: 84863774566     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2012.04.001     Document Type: Article

References (51)

1. McKern N.M., Lawrence M.C., Streltsov V.A., et al. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 2006, 443:218-221.
2. Pandini G., Medico E., Conte E., Sciacca L., Vigneri R., Belfiore A. Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A. J. Biol. Chem. 2003, 278:42178-42189.
3. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 2006, 7:85-96.
4. Zhang H., Pelzer A.M., Kiang D.T., Yee D. Down-regulation of Type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 2007, 67:391-397.
5. Belfiore A., Frasca F., Pandini G., Sciacca L., Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 2009, 30:586-623.
6. Novosyadlyy R., Lann D.E., Vijayakumar A., et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2. Diabetes 2010, 70:741-751.
7. Sciacca L., Costantino A., Pandini G., et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999, 18:2471-2479.
8. Pandini G., Vigneri R., Costantino A., et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin. Cancer Res. 1999, 5:1935-1944.
9. Gualberto A., Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr. Drug Targets 2009, 10:923-936.
10. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat. Rev. Cancer 2008, 8:915-928.
11. Hou X., Harrington S., Macedo L., Weroha S., Brodie A., Haluska P. Hormonal therapies differentially enhance insulin receptor isoform A and erbB receptor up-regulation in response to IGF-1R inhibitor MK-0646 in vivo. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research Apr. 18-22 2009, Abstract, Denver, CO Abstract nr 2812.
12. Hou X., Huang F., Macedo L.F., et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011, 24:7597-7607.
13. Fagan D.H., Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13:423-429.
14. Browne B.C., Crown J., Venkatesan N., et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann. Oncol. 2011, 22:68-73.
15. Haluska P., Carboni J.M., TenEyck C., et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther. 2008, 7:2589-2598.
16. Hailey J., Maxwell E., Koukouras K., Bishop W.R., Pachter J.A., Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol. Cancer Ther. 2002, 1:1349-1353.
17. Pandini G., Wurch T., Akla B., Corvaia N., Belfiore A., Goetsch L. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur. J. Cancer 2007, 43:1318-1327.
18. Cohen B.D., Baker D.A., Soderstrom C., et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 2005, 11:2063-2073.
19. Haluska P., Worden F., Olmos D., et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother. Pharmacol. 2010, 65:765-773.
20. Lee A.V., Yee D. Targeting IGF-1R: at a crossroad, the Golan and Javle article reviewed. Oncology (Williston Park) 2011, 25:535-536.
21. Hendrickson A.W., Haluska P. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Curr. Opin. Investig. Drugs 2009, 10:1032-1040.
22. Buck E., Gokhale P.C., Koujak S., et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 2010, 9:2652-2664.
23. Frasca F., Pandini G., Scalia P., et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell. Biol. 1999, 19:3278-3288.
24. Law J.H., Habibi G., Hu K., et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008, 68:10238-10246.
25. Mulligan A.M., O'Malley F.P., Ennis M., Fantus I.G., Goodwin P.J. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res. Treat 2007, 106:39-47.
26. Singh S.K., Tan Q.W., Brito C., De Leon M., De Leon D. Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women. Growth Horm. IGF Res. 2010, 20:245-254.
27. Ulanet D.B., Ludwig D.L., Kahn C.R., Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10791-10798.
28. Cao L., Yu Y., Darko I., et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008, 68:8039-8048.
29. Carboni J.M., Wittman M., Yang Z., et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 2009, 8:3341-3349.
30. Haluska P., Shaw H.M., Batzel G.N., et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res. 2007, 13:5834-5840.
31. Mathieu M.C., Clark G.M., Allred D.C., Goldfine I.D., Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc. Assoc. Am. Physicians 1997, 109:565-571.
32. Huang J., Morehouse C., Streicher K., et al. Altered expression of insulin receptor isoforms in breast cancer. PLoS One 2011, 6:e26177.
33. Malaguarnera R., Frasca F., Garozzo A., et al. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J. Clin. Endocrinol. Metab. 2011, 96. 766-74.
34. Rowzee A.M., Ludwig D.L., Wood T.L. Insulin-like growth factor type 1 receptor and insulin receptor isoform expression and signaling in mammary epithelial cells. Endocrinology 2009, 150:3611-3619.
35. Hamatani K., Eguchi H., Takahashi K., et al. Improved RT-PCR amplification for molecular analyses with long-term preserved formalin-fixed, paraffin-embedded tissue specimens. J. Histochem. Cytochem. 2006, 54:773-780.
36. Oberli A., Popovici V., Delorenzi M., et al. Expression profiling with RNA from formalin-fixed, paraffin-embedded material. BMC Med. Genomics 2008, 1.
37. Scott A., Ambannavar R., Jeong J., Liu M.L., Cronin M.T. RT-PCR-based gene expression profiling for cancer biomarker discovery from fixed, paraffin-embedded tissues. Methods Mol. Biol. 2011, 724:239-257.
38. Liu M.L., Jeong J., Ambannavar R., et al. Rt-PCR gene expression profiling of RNA from paraffin-embedded tissues prepared using a range of different fixatives and conditions. Methods Mol. Biol. 2011, 724:205-237.
39. Harrington S.C., Haluska P., inventors; US patent application 13/302,358.
40. Bustin S.A., Benes V., Garson J.A., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55:611-622.
41. Sachdev D., Singh R., Fujita-Yamaguchi Y., Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res. 2006, 66:2391-2402.
42. Schweizer M.S., Schumacher L., Rubin M.A. Constructing Tissue Microarrays for Research Use. Current Protocols in Human Genetics 2001, John Wiley & Sons.
43. Haluska P., Hou X., Huang F., et al. Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS-754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo. Proceedings of the 32 Annual CTRC-AACR San Antonio Breast Cancer Symposium Dec. 9-13 2009, Abstract, San Antonio, TX Abstract nr 402.
44. Hou X., Carboni J.M., Macedo L.F., et al. Combined estrogen signaling inhibition and IGF-1R/InsR inhibition with BMS-754807 in estrogen-dependent breast cancer model has synergistic antitumor activity in vitro and in vivo. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research Apr. 18-22 2009, Abstract, Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1743.
45. Mohla S., Stearns V., Sathyamoorthy N., Rosenfeld M.G., Nelson P. The biology of hormone refractory breast and prostate cancer: an NCI workshop report. Cancer Biol. Ther. 2009, 8:1975-1985.
46. Song R.X.D., Chen Y., Zhang Z., et al. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J. Steroid Biochem. Mol. Biol. 2010, 118:219-230.
47. Kaufman P., Ferrero J., Bourgeois H., et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with Exemestane (E) or Fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res. 2010, 70(24 Suppl.). Abstract, Abstract nr S1-4.
48. Richardson A.E., Hamilton N., Davis W., Brito C., De Leon D. Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-alpha and -beta via the IGF-1 and the insulin receptors in breast cancer cells. Growth Factors 2011, 29:82-93.
49. Golan T., Javle M. Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology (Williston Park) 2011, 25:518-526. 29.
50. Avnet S., Sciacca L., Salerno M., et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 2009, 69:2443-2452.
51. Zha J., Lackner M.R. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin. Cancer Res. 2010, 16:2512-2517.